Abolfazli, R.; Sahraian, M.A.; Tayebi, A.; Kafi, H.; Samadzadeh, S.
Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study. J. Clin. Med. 2023, 12, 4937.
https://doi.org/10.3390/jcm12154937
AMA Style
Abolfazli R, Sahraian MA, Tayebi A, Kafi H, Samadzadeh S.
Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study. Journal of Clinical Medicine. 2023; 12(15):4937.
https://doi.org/10.3390/jcm12154937
Chicago/Turabian Style
Abolfazli, Roya, Mohammad Ali Sahraian, Atefeh Tayebi, Hamidreza Kafi, and Sara Samadzadeh.
2023. "Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study" Journal of Clinical Medicine 12, no. 15: 4937.
https://doi.org/10.3390/jcm12154937
APA Style
Abolfazli, R., Sahraian, M. A., Tayebi, A., Kafi, H., & Samadzadeh, S.
(2023). Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study. Journal of Clinical Medicine, 12(15), 4937.
https://doi.org/10.3390/jcm12154937